Tarsus Pharmaceuticals (TARS) Non-Current Assets (2019 - 2026)
Tarsus Pharmaceuticals (TARS) posted quarterly Non-Current Assets of $43.9 million for Q1 2026, up 119.78% year-over-year from $20.0 million in Q1 2025, and up 11.5% quarter-over-quarter from $39.4 million in Q4 2025.
Tarsus Pharmaceuticals (TARS) Non-Current Assets (2019 - 2026) Analysis & Trends
Tarsus Pharmaceuticals' Non-Current Assets history runs 8 years deep, the most recent figure standing at $43.9 million for Q1 2026.
- In Q1 2026, Non-Current Assets rose 119.78% year-over-year to $43.9 million; the TTM figure through Mar 2026 stood at $136.7 million (up 85.48% YoY), while the FY2025 annual figure was $39.4 million, up 94.1% from the prior year.
- Non-Current Assets for Q1 2026 stood at $43.9 million, up from $39.4 million in the prior quarter.
- The five-year high for Non-Current Assets was $43.9 million in Q1 2026, with the low at $2.4 million in Q3 2022.
- The 5-year median for Non-Current Assets is $9.4 million (2023), against an average of $15.0 million.
- The sharpest annual moves came in 2022 and 2023: Non-Current Assets retreated 28.19% in 2022, then jumped 279.35% in 2023.
- Tarsus Pharmaceuticals' Non-Current Assets stood at $2.5 million in 2022, then soared by 276.21% to $9.4 million in 2023, then jumped by 116.73% to $20.3 million in 2024, then soared by 94.1% to $39.4 million in 2025, then increased by 11.5% to $43.9 million in 2026.
- Business Quant data shows TARS's Non-Current Assets at $43.9 million in Q1 2026, $39.4 million in Q4 2025, and $32.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Tarsus Pharmaceuticals | 2.99 Bn | 2.54 Bn | 161.80 Mn | 49.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 49.15 Mn |
| Mar 31, 2026 | 43.91 Mn |
| Dec 31, 2025 | 39.38 Mn |
| Sep 30, 2025 | 32.86 Mn |
| Jun 30, 2025 | 20.57 Mn |
| Mar 31, 2025 | 19.98 Mn |
| Dec 31, 2024 | 20.29 Mn |
| Sep 30, 2024 | 19.18 Mn |
| Jun 30, 2024 | 14.26 Mn |
| Mar 31, 2024 | 8.55 Mn |
| Dec 31, 2023 | 9.36 Mn |
| Sep 30, 2023 | 9.06 Mn |
| Jun 30, 2023 | 5.45 Mn |
| Mar 31, 2023 | 2.57 Mn |
| Dec 31, 2022 | 2.49 Mn |
| Sep 30, 2022 | 2.39 Mn |
| Jun 30, 2022 | 2.55 Mn |
| Mar 31, 2022 | 2.73 Mn |
| Dec 31, 2021 | 2.96 Mn |
| Sep 30, 2021 | 3.32 Mn |